Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

EZH2 inhibition: a promising strategy to prevent cancer immune editing

Friday, February 16, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses a study on EZH2 inhibition as a strategy to prevent cancer immune editing. Published in Epigenomics 2020, the research suggests that targeting EZH2 may enhance the effectiveness of cancer treatments by preventing immune evasion. The findings could lead to improved therapeutic approaches for patients.
Price reaction · baseline $21.6 (2024-02-15 close) · hit pre-market · 3 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
-3.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • EZH2 inhibition shows promise in cancer treatment.
  • The study highlights new strategies to combat immune editing.
  • Potential for improved patient outcomes in cancer therapy.

Full Press Release Details

Paper titled:EZH2 inhibition: a promising strategy to prevent cancer immune editing.
Kang, Eccleston, Clermont et al
Published in Epigenomics 2020

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What is EZH2 inhibition?

EZH2 inhibition refers to the targeting of the EZH2 enzyme to prevent cancer cell immune evasion.

How does EZH2 inhibition help in cancer treatment?

It may enhance the effectiveness of treatments by preventing immune editing in cancer cells.

Where was the study on EZH2 inhibition published?

The study was published in the journal Epigenomics in 2020.

Who conducted the research on EZH2 inhibition?

The research was conducted by Kang, Eccleston, Clermont, and others.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare EZH2 cancer therapy immune editing epigenomics
Last updated: Feb 16, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk